EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system

Jenna Bhimani, Kelli O'Connell, Sonia Persaud, Victoria Blinder, Rachael P Burganowski, Isaac J Ergas, Grace B Gallagher, Jennifer J Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H Kroenke und 11 weitere

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07433-4 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Jenna Bhimani und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Staging, Delivery of Health Care, Integrated. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institute of Health, United States, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The National Comprehensive Cancer Network (NCCN) guidelines recommend a variety of drug combinations with specific administration schedules for the treatment of early-stage breast cancer, allowing physicians to deliver treatments recognizing individual patient complexities, including comorbidities, and patient-physician preference. While use of guideline regimens has shifted over time, there is little data to describe changes in how treatment for early-stage breast cancer has evolved over time. METHODS: In a cohort of 34,109 women treated for stage I-IIIA breast cancer between 2006-2019 at Kaiser Permanente Northern California and Kaiser Permanente Washington, we present the changes in chemotherapy regimens over time, and explore use of NCCN-guideline regimens (GR), guideline regimens used when said regimens were not included in guidelines, referred to as time-discordant regimens (TDR), and non-guideline regimens (NGR). Results are presented by drug combination and over time. RESULTS: Among 12,506 women receiving chemotherapy, 77.4% (n = 9681) received GRs, 9.1% (n = 1140) received TDRs, and 13.5% (n = 1685) received NGRs. In 2006, AC-T (cyclophosphamide-doxorubicin, paclitaxel) was the most common regimen, with TC (cyclophosphamide-docetaxel) becoming the most prevalent by 2019. NGRs were more common in cyclophosphamide-methotrexate-5-fluorouracil (CMF); cyclophosphamide-doxorubicin-paclitaxel-trastuzumab (ACTH); and paclitaxel-trastuzumab (TH). The use of GR has increased over time (p-trend < 0.001), while use of NGR (both in terms of administration schedule and drug combination) and TDR have decreased, although patterns vary by drug combination. CONCLUSION: Chemotherapy delivery has changed markedly over time, with a move toward more use of GR. These data are important for understanding the landscape of chemotherapy delivery in community healthcare settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm StagingDelivery of Health Care, IntegratedPractice Guidelines as TopicHumansFemaleMiddle AgedAgedAdultGuideline AdherenceCalifornia

Stichwörter der Autor:innen

Adherence guidelineBreast cancerChemotherapyClinical practice patterns

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.
  • Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Department of Medicine, Division of Hematology/Oncology and Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.
  • Department of Oncology, Kaiser Permanente Medical Center, Vallejo, CA, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute of the National Institute of Health, United States
  • National Cancer Institute
  • Geoffrey Beene Cancer Research Center

Zitieren

APA

Bhimani, J., O'Connell, K., Persaud, S., Blinder, V., Burganowski, R. P., Ergas, I. J., Gallagher, G. B., Griggs, J. J., Heon, N., Kolevska, T., Kotsurovskyy, Y., Kroenke, C. H., Laurent, C. A., Liu, R., Nakata, K. G., Rivera, D. R., Roh, J. M., Tabatabai, S., Valice, E., …, & Kantor, E. D. (2024). The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07433-4

Vancouver

Bhimani J, O'Connell K, Persaud S, Blinder V, Burganowski RP, Ergas IJ, et al. The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07433-4

BibTeX
@article{Bhimani2024,
  author = {Bhimani, Jenna and O'Connell, Kelli and Persaud, Sonia and Blinder, Victoria and Burganowski, Rachael P and Ergas, Isaac J and Gallagher, Grace B and Griggs, Jennifer J and Heon, Narre and Kolevska, Tatjana and Kotsurovskyy, Yuriy and Kroenke, Candyce H and Laurent, Cecile A and Liu, Raymond and Nakata, Kanichi G and Rivera, Donna R and Roh, Janise M and Tabatabai, Sara and Valice, Emily and Bandera, Elisa V and Aiello Bowles, Erin J and Kushi, Lawrence H and Kantor, Elizabeth D},
  title = {The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07433-4}
}
Kostenlos starten →